Summary: In 145 adults with type 2 diabetes, once-weekly ecnoglutide (0.4, 0.8, or 1.2 mg) reduced HbA1c from baseline by up to 2.39% versus 0.55% with placebo over 20 weeks (P<0.0001), and 71.9% of the 1.2 mg group reached HbA1c at or below 6.5% versus 9.1% with placebo. These are exploratory Phase 2 findings, not confirmed efficacy.
PICO Summary
| Element | Detail |
|---|---|
| Population | 145 adults with inadequately controlled type 2 diabetes (baseline HbA1c >7.5% to ≤10.0%); randomised, double-blind, placebo-controlled, multicentre Phase 2 trial conducted in China. |
| Intervention | Once-weekly subcutaneous ecnoglutide (XW003) at 0.4, 0.8, or 1.2 mg for 20 weeks; the three active arms together with placebo were drawn from the 145 randomised participants. |
| Comparison | Once-weekly placebo injection for 20 weeks (one of the four randomised arms). |
| Outcome | Primary endpoint, HbA1c change from baseline at Week 20: −1.81%, −1.90%, and −2.39% for 0.4, 0.8, and 1.2 mg respectively versus −0.55% for placebo (P<0.0001). HbA1c at or below 6.5% was reached by 71.9% of the 1.2 mg group versus 9.1% with placebo; body-weight reduction of at least 5% occurred in 33.3% of the 1.2 mg group versus 3.0% with placebo. Confidence intervals, absolute risk reduction, and number needed to treat were not reported in the abstract. Ecnoglutide was reported as generally safe and well tolerated. |
Ecnoglutide in type 2 diabetes
Phase 2 RCT · type 2 diabetes · 20 weeks
Once-weekly ecnoglutide 1.2 mg cut HbA1c by 2.39% versus 0.55% with placebo over 20 weeks (P<0.0001). Encouraging but preliminary Phase 2 data; the agent remains investigational.
Expert Commentary
This Phase 2 trial suggests that ecnoglutide, a novel long-acting GLP-1 analog, produces clinically meaningful glycaemic improvement over 20 weeks, with the largest HbA1c reduction and the highest proportion reaching target seen at the 1.2 mg dose. The effect sizes are consistent with the established GLP-1 receptor agonist class, and the verdict here is that the signal is encouraging but preliminary. The principal limitation is that this was a small, short, exploratory study of only 145 participants conducted at a single national registry, so durability, cardiovascular and renal outcomes, and head-to-head performance against approved agents remain entirely unaddressed. Several authors are employees of the manufacturer, Sciwind Biosciences, and the company sponsored the work, which warrants caution when interpreting the favourable tolerability claims. Confidence intervals and number-needed-to-treat were not available, limiting precise effect estimation. Can I use this with my patients? Not yet: ecnoglutide is investigational and not approved, so for a patient needing better glycaemic control today an established GLP-1 receptor agonist remains the appropriate choice. Larger, longer Phase 3 trials with active comparators and hard outcomes should be awaited before this agent enters routine practice.
References
Zhu D, Wang W, Tong G, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024;15(1):8408. doi:10.1038/s41467-024-52353-y